HAEMONETICS CORP — Director's Dealing 2023

Jun 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-06-07

Reporting Person: Strong Stewart W (President, Global Hospital)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-07	Common Stock	M	4483	$56.57	Acquired	21630	Direct
2023-06-07	Common Stock	M	2410	$57.60	Acquired	24040	Direct
2023-06-07	Common Stock	F	5053	$88.00	Disposed	18987	Direct
2023-06-07	Common Stock	S	2538	$88.04	Disposed	16449	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-07	Non-qualified Stock Option (Right to Buy)	$56.57	M	4483	Disposed	2028-05-18	Common Stock (4483)	Direct
2023-06-07	Non-qualified Stock Option (Right to Buy)	$57.60	M	2410	Disposed	2029-05-16	Common Stock (2410)	Direct

Footnotes

F1: This number includes unvested restricted stock units ("RSUs") previously reported.

F2: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.12, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this report.

F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.